Published in Cancer on October 01, 2005
Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer (2011) 1.44
Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring) (2009) 1.41
Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int (2008) 1.25
Cancer screening and preventative care among long-term cancer survivors in the United Kingdom. Br J Cancer (2010) 1.22
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int (2012) 1.05
Health-related quality of life and biomarkers in breast cancer survivors participating in tai chi chuan. J Cancer Surviv (2011) 0.90
An aerobic weight-loaded pilot exercise intervention for breast cancer survivors: bone remodeling and body composition outcomes. Biol Res Nurs (2008) 0.90
Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc (2010) 0.87
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol (2009) 0.87
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer (2009) 0.84
Long-term Toxicity of Cancer Treatment in Older Patients. Clin Geriatr Med (2015) 0.83
Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat (2007) 0.80
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol (2012) 0.79
Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study. Support Care Cancer (2013) 0.79
Interventions to Alleviate Symptoms Related to Breast Cancer Treatments and Areas of Needed Research. J Cancer Sci Ther (2011) 0.78
The evolving role of zoledronic acid in early breast cancer. Onco Targets Ther (2009) 0.77
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J Cancer Res Clin Oncol (2012) 0.77
Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors: a case-control study. J Cancer Surviv (2015) 0.77
Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio. Breast Care (Basel) (2009) 0.76
Soy isoflavone intake and bone mineral density in breast cancer survivors. Cancer Causes Control (2015) 0.75
Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings From the Women's Health Initiative Study. J Clin Endocrinol Metab (2015) 0.75
Detailed methods of two home-based vegetable gardening intervention trials to improve diet, physical activity, and quality of life in two different populations of cancer survivors. Contemp Clin Trials (2016) 0.75
The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J Gen Intern Med (2009) 0.75
Utilization of an Anti-Gravity Treadmill in a Physical Activity Program with Female Breast Cancer Survivors: A Pilot Study. Int J Exerc Sci (2016) 0.75
A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06). Int J Clin Oncol (2013) 0.75
Exercise Recommendations for the Management of Symptoms Clusters Resulting From Cancer and Cancer Treatments. Semin Oncol Nurs (2016) 0.75
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med (2009) 12.38
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Overview of telepathology, virtual microscopy, and whole slide imaging: prospects for the future. Hum Pathol (2009) 3.91
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials (2002) 3.41
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med (2008) 3.12
Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell (2008) 3.08
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol (2003) 3.03
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Researching complementary and alternative treatments--the gatekeepers are not at home. BMC Med Res Methodol (2007) 2.96
The status of public reporting of clinical outcomes in assisted reproductive technology. Fertil Steril (2013) 2.93
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst (2003) 2.64
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause (2010) 2.50
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst (2007) 2.37
Symptom experience after discontinuing use of estrogen plus progestin. JAMA (2005) 2.32
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab (2012) 2.25
Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr (2011) 2.21
AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 2.17
Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med (2005) 2.17
American society of clinical oncology policy statement: disparities in cancer care. J Clin Oncol (2009) 2.12
Low-intensity IVF: real progress? Reprod Biomed Online (2011) 2.08
Gender differences in academic advancement: patterns, causes, and potential solutions in one US College of Medicine. Acad Med (2003) 2.07
Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol (2011) 2.02
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci (2009) 2.01
Complementary and alternative medicine whole systems research: beyond identification of inadequacies of the RCT. Complement Ther Med (2005) 1.97
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med (2008) 1.94
AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med (2005) 1.85
Association of nonmelanoma skin cancer with second malignancy. Cancer (2004) 1.82
Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med (2003) 1.81
Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). Am J Epidemiol (2007) 1.80
Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum (2008) 1.80
Increases in plasma carotenoid concentrations in response to a major dietary change in the women's healthy eating and living study. Cancer Epidemiol Biomarkers Prev (2006) 1.78
Effects of questionnaire-based diagnosis and training on inter-rater reliability among practitioners of traditional Chinese medicine. J Altern Complement Med (2009) 1.77
Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med (2007) 1.75
Telephone counseling intervention increases intakes of micronutrient- and phytochemical-rich vegetables, fruit and fiber in breast cancer survivors. J Nutr (2004) 1.75
Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol (2009) 1.75
Low-fat dietary pattern and lipoprotein risk factors: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 1.73
Statistical issues arising in the Women's Health Initiative. Biometrics (2005) 1.72
Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit. Fertil Steril (2005) 1.72
Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril (2008) 1.72
Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr (2010) 1.67
Insecticide use and risk of rheumatoid arthritis and systemic lupus erythematosus in the Women's Health Initiative Observational Study. Arthritis Care Res (Hoboken) (2011) 1.64
Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reprod Biomed Online (2010) 1.64
The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol (2012) 1.62
The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbance in women with breast cancer: an exploratory study. J Psychosom Res (2003) 1.60
Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol (2009) 1.60
Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS One (2011) 1.60
Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause (2011) 1.59
Gender as risk factor for autoimmune diseases. J Autoimmun (2007) 1.58
Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol (2006) 1.55
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol (2006) 1.54
Randomized trial of two mind-body interventions for weight-loss maintenance. J Altern Complement Med (2007) 1.51
Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med (2006) 1.50
Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril (2010) 1.49
Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol (2011) 1.47
Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause (2010) 1.47
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res (2006) 1.45
Traditional versus telenursing outpatient management of patients with cancer with new ostomies. Oncol Nurs Forum (2004) 1.45
Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (2013) 1.42
Hype or hope? Ethical and practical considerations with clinical research in women with diminished ovarian reserve. Reprod Biomed Online (2012) 1.41
Advanced reproductive age and maternal mortality. Obstet Gynecol (2015) 1.40